Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 951 to 960 of 1000 total matches.
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002 (Issue 1121)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba
EDITORIAL FELLOWS ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Treatment of Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?
Antiplatelet Therapy for Patients with Stents
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008 (Issue 1292)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
The antiplatelet agents aspirin and clopidogrel (Plavix, and others) are used in most patients undergoing percutaneous coronary intervention (PCI) to prevent stent thrombosis and to reduce the occurrence of peri-, post-procedural and late cardiovascular events. Despite a large number of randomized trials of these agents in such patients, the optimal dosage and duration of treatment with these drugs, and whether other drugs should be added, is unclear.
Saxagliptin (Onglyza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R. Simons, M.D., University ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Two New Intra-Articular Injections for Knee Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
; 30:279.
5. R Leighton et al. NASHA hyaluronic acid vs. methylprednisolone
for knee osteoarthritis ...
The FDA has approved a single-injection hyaluronic
acid gel (Durolane – Bioventus) and an extended-release
(ER) formulation of the synthetic corticosteroid
triamcinolone acetonide (Zilretta – Flexion) for intra-articular
(IA) treatment of osteoarthritic knee pain.
Booster Doses of COVID-19 Vaccines
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
at: https://bit.ly/3EdYPVk. Accessed October 29,
2021.
11. R Zhang and T Brennan. FDA review ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) and the adenovirus-based vaccine
manufactured by Johnson & Johnson/Janssen to
include administration of a booster dose in select
populations after primary immunization with either the
same COVID-19 vaccine or a different one.
Drugs for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
Vamousse AirAlle LouseBuster lindane Ovide malathion pyrethrins R&C Rid permethrin Nix Elimite ivermectin ...
Pediculosis capitis (head lice infestations) occur in
all age groups, but especially in elementary school
children. In most cases, transmission occurs by
head-to-head contact. Pharmacologic treatment is
recommended for persons with live lice or eggs (nits)
within 1 cm of the scalp. Topical pediculicides should
be tried first. Oral therapy is occasionally required for
refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92 doi:10.58347/tml.2024.1704a | Show Introduction Hide Introduction
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
IV open-label study
(CrisADe CARE 1). Am J Clin Dermatol 2020; 21:275.
15. R Sidbury et al ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
. Tofacitinib versus methotrexate in rheumatoid
arthritis. N Engl J Med 2014; 370:2377.
22. R Fleischmann et ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.